Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for tough blood cancers: experimental drug targets resistant disease

NCT ID NCT05583552

First seen May 16, 2026 · Last updated May 21, 2026 · Updated 2 times

Summary

This study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) whose cancer did not respond to standard treatments. The goal is to see if the drug can improve blood cell counts and control the disease. Participants who respond may continue treatment until their disease worsens.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU Nantes - Hôtel Dieu

    Nantes, France

  • CHU de Toulouse

    Toulouse, France

  • Hôpital Archet 1

    Nice, France

  • Hôpital Saint-Louis

    Paris, France

  • Klinikum rechts der Isar

    München, Germany

  • Linear Clinical Research

    Nedlands, Australia

  • Marien Hospital Düsseldorf

    Düsseldorf, Germany

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Brisbane and Women's Hospitals

    Brisbane, Australia

  • Universität Jena, Medizinische Fakultät

    Jena, Germany

  • Universität Leipzig, Medizinische Fakultät

    Leipzig, Germany

Conditions

Explore the condition pages connected to this study.